anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1426450 Treating hair L'OREAL 3 April 1973 [4 April 1972] 15845/73 Heading D1P A two-compartment pack for use in the oxidation stage of a permanent waving procedure for hair, contains components which on admixture produce a rise in temperature. The first compartment contains a first component comprising at least one sulphite, metabisulphite, bisulphite or thiourea, and the second compartment contains a second component comprising hydrogen peroxide, the contents of the two compartments being such that after mixing the entire contents of the two compartments the rise in temperature is 15-25‹C and the concentration of hydrogen peroxide in the resulting composition (at the end of the oxidation-reduction reaction) is between 0.5 and 3%, preferably between 0.75 and 1.5% by weight. The self-heating compositions resulting from admixture of the first and second components may be applied in a process for permanently waving hair, by treating the hair, after it has been reduced and rinsed while constrained in a deformed state, with the self-heating composition for a period of 1-15 minutes, followed by removing the constraining means and rinsing the hair. The first component may be in solid form. The second component may contain, in addition to hydrogen peroxide, a thickener e.g .carboxymethyl cellulose, hydroxymethyl cellulose or a wax. Citric acid, phenacetin, hydroxyquinoline sulphate, perfume and dyestuff may also be present.
This study aimed to investigate the ameliorating effects of peach blossom soluble dietary fiber (PBSDF) and polyphenol (PBP) combinations on loperamide (Lop)-induced constipation in mice, together with the possible mechanism of action. The results demonstrated that the combined use of PBSDF and PBP could synergistically accelerate the gastrointestinal transit rate and gastric emptying rate, shorten first red fecal defecation time, accelerate the frequency of defecation, regulate the abnormal secretion of gastrointestinal neurotransmitters and pro-inflammatory cytokines, and down-regulate the expressions of AQP3 and AQP8. Western blotting and RT-qPCR analysis confirmed that PBSDF + PBP up-regulated the protein and mRNA expressions of SCF and C-kit in SCF/C-kit signaling pathway, and down-regulated pro-inflammatory mediator expressions in NF-κB signaling pathway. 16S rRNA sequencing showed that the diversity of gut microbiota and the relative abundance of specific strains, including Akkermansia, Bacteroides, Ruminococcus, Lachnospiraceae_NK4A136_group, and Turicibacter, rehabilitated after PBSDF + PBP intervention. These findings suggested that the combination of a certain dose of PBSDF and PBP had a synergistic effect on attenuating Lop-induced constipation, and the synergistic mechanism in improving constipation might associated with the regulating NF-κB and SCF/C-kit signaling pathway, and modulating the specific gut strains on constipation-related systemic types. The present study provided a novel strategy via dietary fiber and polyphenol interactions for the treatment of constipation.
In colorectal cancer (CRC), KRAS mutations enhance metachronous metastasis, a condition without prognostic biomarkers or preventive measures. The present study demonstrated that KRAS mutation may be a risk factor for CRC metachronous metastasis through meta‑analysis of public databases. A risk scoring model was constructed using machine learning for predicting metachronous metastasis in KRAS‑mutant CRC. Wound healing and Transwell assay indicated that KRAS inhibitors strongly suppress migration and invasion capabilities of high‑risk CRC cells and these findings were validated through ex vivo organoid and a mouse model of splenic‑liver metastasis. Mechanistically, RNA sequencing, reverse transcription‑quantitative PCR and western blot analyses revealed that KRAS inhibitors suppressed epithelial‑mesenchymal transition (EMT) and transforming growth factor β (TGF‑β) signaling. Notably, addition of TGF‑β1 protein partially reversed the inhibitory effects of KRAS inhibitors on CRC. These results suggested that KRAS inhibitors may prevent CRC metachronous metastasis by downregulating TGF‑β‑mediated EMT, suggesting they can be used prophylactically in high‑risk KRAS‑mutant CRC.
The biological heterogeneity of neuroblastoma underscores the need for an in vitro model of each molecularly defined subgroup to investigate tumorigenesis and develop targeted therapies. We have established a permanently growing cell line from a 12-year-old girl who developed a late recurrent stage MS, MDM2-amplified neuroblastoma arising in the liver and performed histological, molecular, cytogenetic, exome, and telomere analyses of the recurrent tumor and the cell line. On histology, the recurrent tumor was immunoreactive for TP53, CDKN1A, and MDM2. A molecular cytogenetic study of the recurrent tumor revealed the amplification of MDM2 but no amplification of MYCN. The established cell line, NBM-SHIM, showed amplification of both MDM2 and MYCN on double-minute chromosomes. A copy number evaluation based on exome data confirmed the finding for MYCN and MDM2 and further identified high ploidy on CDK4 and GLI2 loci in the recurrent tumor and the cell line. The telomere maintenance mechanism on the cell line is unusual in terms of the low expression of TERT despite MYCN amplification and alternative lengthening of telomeres suggested by positive value for C-circle assay and telomere contents quantitative assay. The cell line is unique because it was established from a MYCN-nonamplified, MDM2-amplified, late-relapsed stage MS neuroblastoma, and MYCN amplification was acquired during cell culture. Therefore, the cell line is a valuable tool for investigating neuroblastoma tumorigenesis and new molecular targeted therapies for disrupted ARF-TP53-MDM2 pathway and amplification of MDM2 and CDK4.
The invention provides methods and compositions for treating viral infections. A nuclease is used to cleave viral nucleic acid in an infected cell. The nuclease cleaves viral nucleic acid in a sequence-specific manner and thus does not cleave genes or other important genomic features from a genome of the infected host. In a preferred embodiment, the nuclease is a CRISPR-associated protein such as Cas9 and is delivered to the infected cells as a ribonucleoprotein that includes the Cas9 and a guide RNA designed to target HSV or CMV nucleic acid. Additionally or alternatively, the nuclease can be delivered encoded on a plasmid or as mRNA to be expressed within the target cells. Methods and compositions may be used to treat a patient or may be used to treat tissues, cells, or organs ex vivo.
Active physical therapy students who are healthy and free from any significant pain at the spine will be recruited to participate in intervention endurance training. Participants will be assigned into four equal groups; doing trunk extension form lying on stomach while breathing normally and arching trunk backwards as long as tolerated. Group one will have arms above head, group two will have hands behind head, group three will have hands parallel to the trunk, and group four will receive instructions only and will act as control group. Spinal mobility of forward bending, backwards bending, right and left side bending will be taken. Straight leg raising and quadriceps flexibility will also be taken. Isokinetic measurements including peak torque, peak torque/body weight, average peak torque, work and average power will be taken at baseline, 6 and 8 weeks. Participants will have a training volume of 2 sets of 10 repetitions, 2 minutes rest in between, 2x/day for 6 to 8 weeks. Endurance timing will be measured in seconds using stop watch. If participant managed to maintain the trunk extension position for 4 minutes, time is recorded and it is considered as ceiling time.
FIELD: ophthalmology. SUBSTANCE: patient is subjected to sinustrabeculectomy, during which ohthalmosurgeon additionally makes two through-going incisions of deep- lying layers of sclera. Incisions are made in parallel to two edges of scleral wound. These incisions are intended to let pass into suprachoroidal space edges of nuclear membrane flap made of synthetic cloth LAVSAN (Russia-made equivalent for Therylene or Tergal) in form of isosceles triangle. Flap is grafted in such manner that its vertex would be implanted into anterior chamber, while angles at base would be fixed by interrupted suture. EFFECT: effective treatment of secondary glaucoma. 1 dwg
PURPOSE:To obtain a new tryptamine derivative useful as a therapeutic agent for serotonin nervous system-related diseases, e.g. an antideflection agent, an anti-space sickness agent, an antiemetic drug, an antidizziness agent, an antidepressant, an antianxiety agent or an eating disorder-improving agent. CONSTITUTION:A compound (non-toxic salt) of formula I [R is H, a halogen, a lower alkyl, a lower alkoxy or benzyloxy; (n) is 2 to 5], e.g. 2-{4-[(2-(indol-3-yl) ethyl)amino]butoxy}-5,6,7,8-tetrahydroquinoxaline. This compound can be obtained, e.g. by reacting a compound of formula II (X is a reactive eliminable group for alkylation) with a compound of formula III preferably in the presence of an acid scavenger such as potassium carbonate in an inert solvent such as benzene preferably under a condition of reflux of the solvent.
HIV-1 infection is efficiently controlled by the antiretroviral treatment (ART) but viral persistence in long-lived reservoirs formed by CD4 + T cells and macrophages impedes viral eradication and creates a chronic inflammatory environment. Dasatinib is a tyrosine kinase inhibitor clinically used against chronic myeloid leukemia (CML) that has also showed an anti-inflammatory potential. We previously reported that dasatinib is very efficient at interfering with HIV-1 infection of CD4 + T cells by preserving the antiviral activity of SAMHD1, an innate immune factor that blocks T-cell activation and proliferation and that is inactivated by phosphorylation at T592 (pSAMHD1). We observed that short-term treatment in vitro with dasatinib significantly reduced pSAMHD1 in monocyte-derived macrophages (MDMs) isolated from people with HIV (PWH) and healthy donors, interfering with HIV-1 infection. This inhibition was based on low levels of 2-LTR circles and proviral integration, while viral reverse transcription was not affected. MDMs isolated from people with CML on long-term treatment with dasatinib also showed low levels of pSAMHD1 and were resistant to HIV-1 infection. In addition, dasatinib decreased the inflammatory potential of MDMs by reducing the release of M1-related cytokines like TNFα, IL-1β, IL-6, CXCL8, and CXCL9, but preserving the antiviral activity through normal levels of IL-12 and IFNγ. Due to the production of M2-related anti-inflammatory cytokines like IL-1RA and IL-10 was also impaired, dasatinib appeared to interfere with MDMs differentiation. The use of dasatinib along with ART could be used against HIV-1 reservoir in CD4 and macrophages and to alleviate the chronic inflammation characteristic of PWH.
PURPOSE:To provide the titled agent containing yeast cell or its extract with water as an active component. CONSTITUTION:Cell of yeast (e.g. various yeasts belonging to Saccharomyces genus, Kluyveromyces genus, Torulopsis genus, Trulospora genus or Schizosaccharomyces genus, e.g. Saccharomyces cerevisiae) or its water extract is used as an active component of an cariostatic and antiperiodontosis agent, composition for oral cavity application, or acariostatic and antiperiodontosis food or drink. The water-extract can be produced by subjecting the separated yeast cell to the hot-water extraction at 80-130 deg.C for several min-several hr under pressure or atmospheric pressure to effect sterilization of the cell and centrifuging the product to remove the water-insoluble solid component from the extract. It is used in the form of dentifrice, gargle, troche, chewing gum, etc., containing 0.001-1wt% active component.
FIELD: medicine, biotechnology. SUBSTANCE: invention relates to human semaphoring L (H-Sema-L) and corresponding semaphorins in other species. Invention involves the development of new semaphorins that elicit immunomodulating properties. Proposed semaphorins of type L (Sema-L) comprise N-terminal signal peptide, typical Sema-domain and immunoglobulin-like domain at C-terminal region and hydrophobic domain that represents potential transmembrane domain. Invention relates to also nucleic acids encoding these semaphorins and to application of these semaphorins. The advantage of invention involves that new semaphorins elicit modulating properties. EFFECT: valuable biological properties of semaphorins. 20 cl, 8 dwg, 15 tbl, 11 ex
PURPOSE:To obtain oil-in-water type emulsion useful for fields of drug or cosmetic, etc., having liposome of uniform particle diameter and stability in storing for more than two years containing dibasic acid-bonded glycolipid. CONSTITUTION:100mol phospholipid is mixed with 0.1-20mol cholesterol and 0.1-20mol dibasic acid-bonded glycolipid composed of monosaccharide or oligosaccharide containing 2-5 pieces of constituting monosaccharide having ester bonding with 2-7C dibasic acid in an amount of 1-2mol to 1mol monosaccharide and 6-24C fatty acid in an amount of 1-2mol to 1mol monosaccharide and processed in a normal method to obtain liposome having <=0.5mum particle diameter. Oil-in-water type emulsion is obtained by mixing 100 pts.wt. triglyceride and diglyceride with 2-100 pts.wt. dibasic acid-bonded glycolipid having the same composition as the above-mentioned glycolipid. One or both of hydrophilic drug and lipophilic drug are able to be mixed with the liposome and the oil-in-water type emulsion.
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a metabolite of naltrexone, such as 6-??-naltrexol or a prodrug of a naltrexone metabolite, and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) and/or a melanocortin 4 receptor (MC4-R), and/or increases the concentration of ??-MSH in the central nervous system. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity with a metabolite of naltrexone, such as 6-??-naltrexol or a prodrug of a naltrexone metabolite, and treating that individual to enhance ??-MSH activity, e.g., by administration of a second compound causes increased agonism of MC3-R and/or MC4-R, and/or increases the concentration of ??-MSH in the central nervous system.
Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
A 46-year-old man underwent endoscopic ultrasound (EUS)-guided transgastric drainage with subsequent direct endoscopic necrosectomy (DEN) for an infected walled-off pancreatic necrosis (WOPN). Following treatment, he improved clinically with resolution of fever and substantial reduction in size of the WOPN. He was discharged with indwelling plastic stents which were to be removed after complete resolution of the WOPN. Follow-up CT and EUS 1 months later showed spontaneous stents dislodgement and a residual pancreatic fluid collection (PFC) measuring 4.0×2.3cm, for which re-intervention was technically demanding due to the small size. As he was asymptomatic, a decision was made to manage him expectantly for spontaneous resolution of the residual PFC. However, against our expectation, 1 year later he presented with recurrent fever to 40.1 °C. An hepatic abscess was identified on CT scan, which also revealed the residual PFC, though it was further reduced in size. After one month of antibiotic treatment, follow-up CT revealed that the hepatic abscess had resolved. Concurrently, complete resolution of residual PFC was also observed. EUS-guided drainage/debridement is a first-line therapy for WOPN. Remnant PFC due to premature stent dislodgement may persist as an insidious source of infection in which dormant pathogens may become reactivated sometime and culminate in a flare-up. Since the venous drainage of the pancreatic region ends up in the portal vein, occurrence of the hepatic abscess in the presence of the residual PFC should be considered as causal rather than coincidental. At least we couldn't help arousing a high suspicion of their cause-and-effect relationship. Therefore, despite its being technically challenging, timely reintervention with measures such as EUS-guided needle puncture and irrigation so as to thoroughly eradicate the residual PFC burden should be advocated to reduce the likelihood of late on-set local or distant infection.
PURPOSE: Transcatheter aortic valve replacement (TAVR) induced coronary artery obstruction (CAO) is a rare but devastating complication. Current preventive strategies need additional procedures and may be associated with adverse events. This study aimed to evaluate the early safety and efficacy of stand-alone TAVR using the J-Valve (Jianshi JieCheng Medical Technology Co. Ltd, Shanghai, China) in patients at potential high risk for CAO.
PATIENTS AND METHODS: CAO was defined as coronary ostia obstruction requiring intervention. Patients at potential high risk for CAO were identified retrospectively from 673 consecutive patients who underwent TAVR from January 2015 to July 2021 at Zhongshan Hospital, Fudan University. Procedural results and early outcomes were evaluated according to Valve Academic Research Consortium-3 definitions.
RESULTS: A total of 20 consecutive patients (age 72 ± 9 years; 85% female;) were included. The Society of Thoracic Surgeons-Predicted Risk of Mortality was 5% (interquartile range, 4 to 10%). All patients (100%) had at least 2 classical risk factors for CAO by pre-procedural computed tomography analysis, and 90% patients had native aortic valve diseases. TAVR was successful in 95% of cases, with only 1 patient requiring second device implantation. Early safety at 30 days was achieved in all cases without death. All patients were free from CAO, stroke or emergency reintervention. Post-procedural mean aortic valve gradient was 7 (interquartile range, 4, 12) mmHg, and none/trace or mild aortic regurgitation was present in all patients.
CONCLUSION: Stand-alone TAVR using the J-Valve may mitigate the risk of TAVR-induced CAO.
The invention discloses a spearmint essential oil bath salt. The spearmint essential oil bath salt comprises, by weight, 30-50 parts of sea salt, 10-30 parts of sodium sulfate, 10-30 parts of sodium dihydrogen phosphate, 5-10 parts of pearl powder, 5-10 parts of dry aloe gel, 1-5 parts of sodium carboxymethyl inulin, 1-5 parts of cocamidopropyl betaine, 1-5 parts of sodium laneth sulfate, 0.5-3 parts of peppermint oil, 0.5-3 parts of eucalyptus oil, 1-5 parts of spearmint essential oil and 0.5-3 parts of tea tree oil. A making method of the spearmint essential oil bath salt comprises the following steps: 1, preparing the dry aloe gel; 2, absorbing essential oils by the pearl powder; and 3, making the spearmint essential oil bath salt. The spearmint essential oil bath salt is pale green in color, can generate abundant foams after meeting water, and has very good cooling and refreshing feeling and spirit raising effect. An aqueous solution of the spearmint essential oil bath salt is weakly acidic to neutral, and has no damages to skins. The spearmint essential oil bath salt has very good moisturizing and whitening functions, and can be used for a long term.
Chronic diabetes mellitus compromises the vascular system, which causes organ injury, including in the lung. Due to the strong compensatory ability of the lung, patients always exhibit subclinical symptoms. Once sepsis occurs, the degree of lung injury is more severe under hyperglycemic conditions. The α7 nicotinic acetylcholine receptor (α7nAChR) plays an important role in regulating inflammation and metabolism and can improve endothelial progenitor cell (EPC) functions. In the present study, lung injury caused by sepsis was compared between diabetic rats and normal rats. We also examined whether α7nAChR activation combined with EPC transplantation could ameliorate lung injury in diabetic sepsis rats. A type 2 diabetic model was induced in rats via a high-fat diet and streptozotocin. Then, a rat model of septic lung injury was established by intraperitoneal injection combined with endotracheal instillation of LPS. The oxygenation indices, wet-to-dry ratios, and histopathological scores of the lungs were tested after PNU282987 treatment and EPC transplantation. IL-6, IL-8, TNF-α, and IL-10 levels were measured. Caspase-3, Bax, Bcl-2, and phosphorylated NF-κB (p-NF-κB) levels were determined by blotting. Sepsis causes obvious lung injury, which is exacerbated by diabetic conditions. α7nAChR activation and endothelial progenitor cell transplantation reduced lung injury in diabetic sepsis rats, alleviating inflammation and decreasing apoptosis. This treatment was more effective when PNU282987 and endothelial progenitor cells were administered together. p-NF-κB levels decreased following treatment with PNU282987 and EPCs. In conclusion, α7nAChR activation combined with EPC transplantation can alleviate lung injury in diabetic sepsis rats through the NF-κB signaling pathway.
No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count \< 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.
OBJECTIVE: To assess the role of the systolic blood pressure polygenic risk score (SBP-PRS) in antihypertensive treatment initiation and its comparative efficacy with coronary artery calcium (CAC) scores.
PATIENTS AND METHODS: This retrospective cohort study included participants with whole genome sequencing data who underwent CAC scanning between 1971 and 2008, were free of prevalent cardiovascular disease (CVD), and were not taking antihypertensive medications. The cohort was stratified by blood pressure (BP) treatment group and SBP-PRS (low/intermediate, first and second tertiles; high, third tertile) and CAC score (0 vs >0) subgroups. The primary outcome was the first occurence of adjudicated coronary heart disease, heart failure, or stroke during 10-year follow-up. The 10-year number needed to treat (NNT) to prevent 1 event of the primary outcome was estimated. A relative risk reduction of 25% for the primary outcome based on the treatment effect of intensive control (SBP <120 mm Hg) of hypertension in SPRINT (Systolic Blood Pressure Intervention Trial) was used for estimating the NNT.
RESULTS: Among the 5267 study participants, the median age was 59 years (interquartile range, 51-68 years); 2817 (53.5%) were women and 2880 (54.7%) were non-White individuals. Among 1317 individuals with elevated BP/low-risk stage 1 hypertension not recommended treatment, the 10-year incidence rate of the primary outcome was 5.6% for low/intermediate SBP-PRS and 6.3% for high SBP-PRS with NNTs of 63 and 59, respectively. Similarly, the 10-year incidence rate of the primary outcome was 2.9% for CAC score 0 and 9.7% for CAC score greater than 0, with NNTs of 117 and 37, respectively.
CONCLUSION: Including genetic information in risk estimation of individuals with elevated BP/low-risk stage 1 hypertension has modest value in the initiation of antihypertensive therapy. Genetic risk and CAC both have efficacy in personalizing antihypertensive therapy.